ESMO 2018 | Challenges of nmCRPC management: to treat or not?

Robert Jones, MD, PhD, of the University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses the challenges surrounding the management of non-metastatic castration-resistant prostate cancer (nmCRPC). Prof. Jones reflects on current trials demonstrating a delay in the onset of metastatic disease, and whether this is a meaningful and preferred endpoint. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.